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Papillary carcinoma of the thyroid: methylation is not involved in
the regulation of MET expression
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Hypomethylation has been reported to be responsible for the activation of several oncogenes. The possibility that hypomethylation is
involved in the regulation of MET transcription was investigated through the analysis of the methylation status of one CpG island
containing 43 CpGs in six cases of papillary carcinoma, in the corresponding normal thyroid tissue, and in two cases of hyperplastic
goitre. Evidence of methylation was not found in any of the analysed CpG.
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The Met oncogene encodes a trans-membrane tyrosine kinase
identified as the receptor for hepatocyte growth factor (HGF)
(Giordano et al, 1989; Naldini et al, 1991). Immunohistochemical
studies have demonstrated that Met protein is intensely expressed
in tumour cells of 495% cases of thyroid papillary carcinoma. In
tumour tissue, the levels of RNA transcripts for MET are 10–100-
fold higher than in the surrounding normal thyroid (Di Renzo et al,
1992). Gene expression studies have demonstrated that MET gene
is one of the 23 genes, which are significantly more expressed in
papillary carcinoma (Huang et al, 2001). Mutations, amplifications
or other alterations of the MET gene have not been recognised,
raising the possibility that an aberrant transcriptional regulation
may play a critical role in gene activation. Evidence for activation
of oncogenes by specific gene demethylation in cancer has been
reported in the body of several oncogenes including cMYC, c-JUN,
HOX11 and H-RAS (Vachtenheim et al, 1994; Watt et al, 2000).
Since the MET promoter is a 697bp 50-untranslated region that
contains a typical CpG island spanning, with a frequency of CpGs
10 times greater than in the total gene (Accession no. Z26936), in
the present study, we have explored the possibility that an altered
methylation status of the MET promoter is involved in the
abnormal expression of Met protein in papillary carcinoma.
MATERIALS AND METHODS
Immunohistochemistry
Expression of Met protein was investigated in 137 cryopreserved
samples of thyroid tissue involved by various pathological
conditions. Fragments of fresh tissue were embedded in optimal
cryopreserving tissue (OCT) compound (Miles, Elkhart, IN, USA),
snap-frozen in liquid nitrogen, and stored at  801C until
sectioning. Met protein was demonstrated with the DO-24 mouse
monoclonal antibody.
DNA extraction
For DNA extraction, 40 cryostat sections 10mm each were cut from
six cases of papillary carcinoma of the thyroid (two follicular and
four usual-type papillary carcinoma; female : male ratio was 5:1,
and the mean age was 45 years), from the corresponding
peritumoral normal thyroid tissue, and from two cases of
hyperplastic goitre. They were added 1ml of lysis solution
containing 10ml Tris-HCl pH 8, 1 M,1 0 ml EDTA 0.5 M,2 5 ml SDS
20%, 20ml proteinase K 10mgml
 2, and were incubated at 371C
overnight. DNA was extracted using phenol–chloroform method.
Bisulphite-PCR methylation analysis
Sodium-bisulphite modification of genomic DNA and PCR were
performed according to Frommer’s method (Frommer et al, 1992).
Bisulphite causes deamination of cytosine that is transformed into
uracyl (thymine) unless the cytosine is methylated, in this case it
remains as cytosine. Briefly, 8mg of genomic DNA was digested
with 10U of EcoR1 (PROMEGA) for 1h at 421C. DNA was purified
using phenol–chloroform–isoamylic alcohol, precipitated using
ethanol and sodium acetate and resuspended in water. It was
denatured with 3 M NaOH for 20min at 421C, treated with 3 M
sodium bisulphite (SIGMA-ALDRICH, St Louis, MO, USA) (pH 5)
and 10mM hydroquinone for 18h at 551C. After treatment, DNA
was purified using a Wizard DNA Clean-up kit (SIGMA-ALDRICH,
St Louis, MO, USA) and desulphonated with 0.3 M NaOH and
neutralised with 3 M ammonium acetate. To bisulphite-treated
DNA, 10mg of glycogen was added, precipitated with ethanol and
resuspended in 20ml sterile distilled water. PCR amplification was
performed with 5ml of treated DNA. The sequence of interest in the
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primers: (sense) 50 GGT TGT GTT AAT TTT AGA TT 30,
(antisense) 50 ACT ACC CTA CCA ATA ACT CA 30. The specific
PCR product was 380bp.
Bisulphite sequencing
Amplified bisulphite-PCR products were subcloned into TA vector
system (Invitrogen, San Diego, CA, USA), according
to the manufacturer’s instruction. Single colonies were amplified
according to the manufacturer’s instructions. DNA sequence
analysis was carried out by automated DNA sequencers (Applied
Biosystems, Foster City, CA, USA) using Big Dye Terminator
Version 1 (Applied Biosystems). In all, 10 independent clones
per case were analysed. Bisulphite treatment efficiency was
proven by the complete conversion of the C to T in all sequences
analysed.
RESULTS
The pattern of expression of Met protein was investigated in frozen
sections of 137 thyroid samples (Table 1). A marked reactivity for
the protein was observed in tumour cells of 61 out of 61 cases of
papillary carcinoma (Figure 1A); a much weaker staining was
present in the rim of peritumoral normal follicles with tall
epithelium, whereas normal follicles with flat epithelium were not
stained. Met protein expression was investigated in frozen sections
of 76 thyroid samples involved by pathological conditions other
than papillary carcinoma. Among tumours, membrane staining for
Met protein was observed in two out of three insular carcinomas,
in two out of three undifferentiated carcinomas, and in one out of
four Hu ¨rthle cell tumours. A weak cytoplasm staining was
observed in four follicular carcinomas, and in four out of 16
follicular adenomas. In non-neoplastic conditions, a marked
expression of Met protein was observed in follicles embedded in
a chronic inflammatory reaction (Figure 1B), whereas weak
staining was observed in tall cell follicles of seven out of 38
hyperplastic goitres.
The possibility that methylation is involved in the regulation of
MET transcription was investigated through the analysis of the
methylation status of 43 CpGs in six cases of papillary carcinoma,
in the corresponding normal thyroid tissue, and in two cases of
hyperplastic goitre (Figure 2). Evidence of methylation was not
found in any of the analysed CpG.
Table 1 Immunohistochemical expression of Met protein and methylation of MET promoter in papillary carcinoma and in other pathological conditions of
the thyroid
a
Histology No. cases Age mean7s.d. Sex F/M
Met-positive
cases
MET promoter
methylation
Papillary carcinoma 61 41712 49/12 61 0/6
b
Peritumoral normal thyroid tissue 45  /+
c 0/6
Insular carcinoma 3 42720 2/1 3 nd
Anaplastic carcinoma 3 6772 3/0 3 nd
Follicular carcinoma 4 3476 3/1 4 nd
Oncocytic carcinoma 4 47713 4/0 2/4 nd
Medullary carcinoma 1 51 0/1 0 nd
Follicular adenoma 20 45714 14/6 4/20 nd
Thyroiditis 3 4975 3/0 2/3 nd
Nodular hyperplasia 38 52711 32/6 7/38 0/2
aFrozen sections were immunostained with DO24 mouse monoclonal antibody.
bMethylation status of 43 CpGs of the Met promoter in six cases of papillary carcinoma, in the
corresponding normal thyroid tissue, and in two cases of hyperplastic goitre was investigated. Sodium bisulphite modification of genomic DNA and PCR were performed
according to Frommer’s method (see Materials and Methods).
cA weaker staining was present in the rim of peritumoral normal follicles with tall epithelium; whereas normal
follicles with flat epithelium were not stained. nd¼not determined.
Figure 1 (A) Papillary carcinoma of the thyroid immunostained for Met
protein with DO 24 monoclonal antibody. The tumour is intensely and
diffusely positive; the peritumoral normal thyroid follicles are not stained
( 100). (B) Chronic thyroiditis immunostained for Met protein. Only
those follicles infiltrated and surrounded by inflammatory cells are stained
( 250) (ABC-peroxidase, counterstained with haematoxylin).
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In the present study, we provide further evidence that Met protein
is highly expressed in papillary carcinoma cells, whereas it is
absent or poorly expressed in normal thyroid follicles; moreover,
we demonstrate for the first time that the different patterns of
expression are not due to an altered methylation status of the MET
promoter.
The rationale for our study derives from previous reports
showing that hypomethylation is a kind of molecular mechanism
leading to promoting high expression of oncogenes that encodes
for some proteins with tyrosine kinase activity (Clark and Melki,
2002). They include several members of the Eph family of receptor
tyrosine kinases (RTK) (Dottori et al, 1999), the c-fms oncogene
that encodes for CSF 1R (Cui et al, 2001), and the erbB2/neu (Zhou
et al, 2001).
Finally, in other studies on papillary carcinoma of the thyroid it
was shown that abnormal methylation may occur in tumour cells,
and is probably responsible for loss or for decreased expression of
several genes including TSH receptor (TSHR) (Xing et al, 2003a)
the Pendred syndrome gene SLC26A4 (Xing et al, 2003b), the Ras
association domain family 1A gene (RASSF1A) (Schagdarsurengin
et al, 2002), the metallothionein heavy metal binding protein gene
(MT1G) (Huang et al, 2003) and the high-affinity cellular retinoic
binding protein (CRABP1) (Huang et al, 2003).
Our findings strongly suggest that molecular mechanisms other
than hypomethylation of the gene are responsible for the high
expression of Met protein in papillary carcinoma of the thyroid. So
far, it has been demonstrated that insertion of activated RAS and
RET in normal thyroid cells causes upregulation of MET
transcription (Ivan et al, 1997). The frequent occurrence of RET
rearrangements in papillary carcinoma (Elisei et al, 2001; Soares
et al, 2003) and the recent observation that a consistent number of
nonrearranged cases have an activating mutation of BRAF that also
cause signal transduction through the RET–RAS pathway
(Fukushima et al, 2003) are consistent with the possibility that
dysregulation of MET transcription is caused by the genetic
transforming alterations specifically associated with this histotype.
In addition, it was recently shown that tumour hypoxia may cause
an increased transcription of MET through the upregulation of the
hypoxia inducible factor-1 (HIF-1), which has two binding sites on
the MET promoter (Pennacchietti et al, 2003). In a recent study, we
have reported that HIF-1 is upregulated in tumour cells of most
cases of papillary carcinoma and that histological alterations
suggestive of a hypoxic condition are frequently present in this
specific tumour (Scarpino et al, 2004).
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Figure 2 Methylation status of 43 CpGs of the Met promoter in six cases of papillary carcinoma, in the corresponding normal thyroid tissue, and in two
cases of hyperplastic goitre was investigated. Sodium-Bisulphite modification of genomic DNA and PCR were performed according to Frommer’s method
(see Materials and Methods). In all, 10 colonies were analysed for each sample. Black and white areas represent methylated and unmethylated CpG sites,
respectively.
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